KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Amortization of Deferred Charges (2017 - 2025)

Historic Amortization of Deferred Charges for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $5.0 million.

  • Amneal Pharmaceuticals' Amortization of Deferred Charges fell 3734.43% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year decrease of 523.68%. This contributed to the annual value of $29.1 million for FY2024, which is 15196.57% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Amortization of Deferred Charges of $5.0 million as of Q3 2025, which was down 3734.43% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $8.0 million in Q3 2024 and a low of $2.1 million during Q1 2023
  • For the 5-year period, Amneal Pharmaceuticals' Amortization of Deferred Charges averaged around $4.1 million, with its median value being $2.4 million (2021).
  • In the last 5 years, Amneal Pharmaceuticals' Amortization of Deferred Charges surged by 24002.54% in 2024 and then tumbled by 3734.43% in 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $2.3 million in 2021, then dropped by 9.61% to $2.1 million in 2022, then skyrocketed by 121.46% to $4.7 million in 2023, then soared by 46.16% to $6.8 million in 2024, then dropped by 26.21% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q3 2025, $6.9 million for Q2 2025, and $6.8 million during Q1 2025.